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espite advances in diagnosis and therapy, esophageal
denocarcinoma remains an aggressive and usually le-
hal tumor. This review focuses on the epidemiology of
sophageal adenocarcinoma and its presumed precur-
or lesion, Barrett’s esophagus; the pathogenesis of the
ancer; advances in treatment of adenocarcinoma and
arrett’s esophagus; and strategies for cancer preven-
ion. Emphasis is placed on recent literature. Although
he absolute number of cases of adenocarcinoma in the
nited States is still small, the incidence of this cancer
as increased dramatically in the last 40 years, and
denocarcinoma is now the predominant form of esoph-
geal cancer in this country. Recent evidence suggests
hat Barrett’s esophagus is more prevalent in asymp-
omatic individuals than previously appreciated. The
athogenesis of Barrett’s esophagus is poorly under-
tood. Given that some subjects will have repeated
outs of severe erosive esophagitis and never develop
arrett’s esophagus, host factors must play an impor-
ant role. The utility of neoadjuvant radiation and che-
otherapy in those with adenocarcinoma, although they
re widely practiced, is not of clear benefit, and some
uthorities recommend against it. Ablative therapies, as
ell as endoscopic mucosal resection, hold promise for
hose with superficial cancer or high-grade dysplasia.
ost series using these modalities feature relatively
hort follow-up, and longer-term data will be necessary
o better describe the effects of these therapies. The
alue of chemoprevention in subjects with dysplastic
arrett’s esophagus by use of cyclooxygenase 2 inhibi-
ors, nonsteroidal anti-inflammatory drugs, or proton
ump inhibitors is unknown. Similarly, although endo-
copic screening is widely practiced, its value in patients
ith chronic gastroesophageal reflux disease symptoms
s of unproven value, and recommending bodies are
ivided as to its practice.
ecause of its rapidly increasing incidence over the last
40 years, esophageal adenocarcinoma has gone from a
omewhat esoteric disease entity to the predominant form of
sophageal cancer in the United States. Although still a rare
ause of cancer death internationally, esophageal adenocar-
inoma has become a significant health concern in Westernountries. Given the poor prognosis associated with the
isease, a better understanding of the pathogenesis of the
isease and the factors associated with increased risk is
ssential. Also, strategies for prevention of esophageal ade-
ocarcinoma are hotly contested.
The following review will focus on new developments
n the field of Barrett’s esophagus (BE) and esophageal
denocarcinoma. Given the myriad aspects of these dis-
ase states, an exhaustive review of all that is known
bout them is beyond the scope of this article. Therefore,
his work will concentrate on the epidemiology of the
isease states, the pathogenesis of the cancer, advances in
reatment, and strategies for cancer prevention. Special
mphasis will be placed on recent data, with effort to





The incidence of esophageal adenocarcinoma in
he United States has increased approximately 300%–
00% in the last 40 years.1–3 Although previous mis-
lassification of some esophageal adenocarcinomas as gas-
ric cardia tumors may be in part responsible for the
oted increase, it does not likely explain the entire
ncrease. If misclassification were to explain all of the
ncrease, a concomitant decrease in the number of gastric
ardia tumors might be expected over the same time
eriod. The opposite is true; the incidence of gastric
ardia tumors has not decreased and may have actually
ncreased over this period.4,5
Less clear is the trend in the incidence of BE. Because BE
s thought to be the precursor lesion to most or all cases of
denocarcinoma of the esophagus, increases in cancer might
Abbreviations used in this paper: BE, Barrett’s esophagus; EMR,
ndoscopic mucosal resection; GERD, gastroesophageal reflux dis-
ase; HGD, high-grade dysplasia; PDT, photodynamic therapy.





















































































May 2005 BARRETT’S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA 1555e expected to be preceded by increases in the incidence of
E. Longitudinal single-center studies do show an increase
n diagnosis of BE over the past several decades.6,7 However,
his increasing trend mirrors the increasing use of upper
ndoscopy. It may, therefore, mean that the increased inci-
ence of BE described in these studies is due to increased
pportunity for detection, as well as the increasing appre-
iation of BE as a risk factor for cancer, as opposed to a true
ncrease in prevalence.
The increasing trend in esophageal adenocarcinoma
losely resembles the epidemic increase in obesity in the US
opulation.8,9 Additionally, obesity has been strongly asso-
iated as a risk factor for esophageal adenocarcinoma, even
fter controlling for the severity of reflux symptoms.10,11
hese 2 facts have led authorities to suggest a causal rela-
ionship between trends of increasing obesity and resultant
sophageal adenocarcinoma in the US population.12–14 Al-
hough such a relationship is certainly plausible, no causal
hain has been definitely proven, and changes in other
nvironmental exposures over the last 50 years may account
or all or part of the observed increase.
One recent important contribution to this field has been
he demonstration of the prevalence of BE in asymptomatic
opulations. BE has long been recognized as a possible
omplication of chronic reflux disease. However, 40% or
ore of esophageal adenocarcinoma is found in subjects
ithout previous symptoms of reflux15–17—an observa-
ion that is inconsistent with the theory that BE arises
rom gastroesophageal reflux disease (GERD) and is the
redisposing lesion to adenocarcinoma. This apparent
ontradiction may be at least partially explained by
ecent prevalence data of BE in asymptomatic popula-
ions. Gerson et al18 performed upper endoscopy on 110
ubjects with no or negligible GERD symptoms who
ere presenting for colorectal cancer screening. The sur-
rising and somewhat unsettling finding in this primar-
ly Veterans Administration Medical Center cohort was
hat almost 25% of those with no GERD symptoms
arbored BE, and 8% of the subjects had long-segment
isease (3 cm). Other groups19,20 have found that
esser, but still substantial, proportions of asymptomatic
ndividuals have BE (Table 1). Currently unknown is
hether these asymptomatic individuals with BE have
able 1. Prevalence of BE in Asymptomatic Cohorts
Study Year Patient population
erson et al18 2002 Veterans Administration medic
ex et al19 2003 University hospital
eVault et al20 2004 Academic practiceR, not reported.he same increased risk of cancer that has been shown in
revious, symptomatic cohorts that have been followed
p longitudinally.
Also unknown is the exact risk of cancer in subjects with
E. Initial reports pegged this risk at 1% or more per year.
ore recent reports and a meta-analysis have suggested this
isk to be approximately half that amount.21–24 Of course,
hese analyses provide rough estimates based on accumu-
ated data from cohorts for multiple years. It is quite pos-
ible (perhaps even likely) that cancer risk is unevenly
pread in any given subject’s “Barrett’s lifetime.” For in-
tance, it may be that the initial period immediately after
he development of the BE is a critical time in which a
ubgroup of subjects experience rapid progression through
egrees of dysplasia to cancer. Conversely, perhaps nondys-
lastic BE of 10 years’ duration is at very little, if any, risk
f progression. Because the exact time of development of BE
n subjects diagnosed with the condition is unknown, we




BE is thought to be a sequela of chronic reflux
isease. Subjects with chronic reflux disease seem to
arbor BE 5%–15% of the time.25–27 However, it is
nclear why some subjects develop severe recurrent ero-
ive esophagitis and never develop BE, whereas others
ith relatively few symptoms and little or no inflamma-
ory disease on upper endoscopy develop long segments
f severely dysplastic disease. It has been suggested that
genetic predisposition to the development of BE might
e a necessary prerequisite to the disease. However, to
ate, a “Barrett’s gene” (or genes) has remained elusive.
everal groups have attempted to study the heritability
f BE as presumptive evidence of a genetic contribution
o the disease. Family cohort studies have shown that BE
ccurs in family groups more frequently than would be
xpected by chance.28 However, if there is a Barrett’s
ene, the penetrance of the phenotype must be low,
ecause most first-degree relatives of those with BE do
ot have BE themselves.29
n Prevalence of BE
Prevalence of
long-segment BE
nter 110 25% 7%
556 5.6% 0.36%





























































































1556 NICHOLAS J. SHAHEEN GASTROENTEROLOGY Vol. 128, No. 6Exactly where the progenitor cells leading to BE arise is
matter of debate. Studies using cell markers suggested
hat BE arose from pluripotent cells found in the esophagus,
hich, in the presence of an acidic milieu, developed into
olumnar epithelium.30,31 Recent work from Sarosi et al,32
owever, support an alternative explanation. Using a rodent
odel of BE, this group was able to show that the progen-
tor cells for BE arose in the animal’s bone marrow. The
echanism by which these cells differentiate and the factors
eading to the propagation of columnar instead of squamous
ucosa are still largely unknown.
BE is thought to progress through stages of dyspla-
ia to cancer, and, indeed, one of the strongest known
redictors of cancer risk in the setting of BE is the
egree of dysplasia. Subjects with nondysplastic BE
nd low-grade dysplasia have low rates of progression,
hereas those with high-grade dysplasia (HGD) may
xperience disease progression at rates higher than
0% per year. 33,34 Additionally, surgical series show
oncurrent undetected cancer in the resection speci-
en in 50% or more of patients with HGD.35–37 It has
een more recently appreciated, however, that the
rogression through grades of dysplasia is neither
rderly nor inexorable. Indeed, subjects may jump
rom nondysplastic BE straight to HGD or cancer
ithout an intervening detectable low-grade dysplasia
hase.38 Alternatively, subjects with HGD may un-
ergo apparent regression of the disease and spend
onths or even years with no detectable dysplasia
hatsoever. Data on disease progression in BE are
ompromised by our random-sampling endoscopic bi-
psy techniques. Almost all the data available on
rogression rates in BE are from studies using a ran-
om biopsy method. Even groups that use jumbo
orceps and 1-cm, 4-quadrant biopsies leave the vast
ajority of the mucosa unsampled. It is difficult to
now what percentage of apparent disease regression is
eal and what is due to random sampling error missing
mall or mosaic areas of more advanced dysplasia.
lthough more sophisticated methods of sampling BE
y using vital stains or magnification of mucosal crypt
atterns have been described,39 – 42 these methods have
ot been broadly adopted because of cost, increased
ime requirements, and lack of sufficient evidence of
he effects of the methods on important outcomes.
Advances in Treatment
Neoadjuvant and Surgical Therapy for
Cancer
The prognosis for esophageal adenocarcinoma re-
ains dismal, with a 5-year survival for all comers of ppproximately 20%.43–45 This poor result is due in part
o the advanced stage of the cancer when it is usually
iagnosed. More than 50% of those with this cancer
resent with stage III or IV disease.45,46 However, some
ecent strides have been made in elucidating the best care
or those with adenocarcinoma.
After initial enthusiasm for neoadjuvant chemotherapy as
n adjunct to surgery, a well-performed randomized con-
rolled trial showed that neoadjuvant chemotherapy before
esection does not improve survival.47 More promising have
een the results of studies combining neoadjuvant chemo-
herapy with radiation therapy. Unblinded studies of neo-
djuvant chemoradiation showed that approximately 25%
f those undergoing therapy achieved a complete response
nd that those undergoing therapy had improved survival
ompared with historical controls.48–50 Given these data,
rospective randomized studies have been conducted com-
aring multimodality therapy with surgery alone. These
rials have given somewhat conflicting data. Walsh et al51
andomized 113 patients with adenocarcinoma to undergo
ither surgery alone or neoadjuvant chemotherapy and ra-
iation with surgery afterward. The chemotherapy regimen
as 5-fluorouracil and cisplatin based, and 40 Gy of radi-
tion was delivered. These investigators found a significant
ownstaging of tumors in the multimodality group; fewer
ubjects in this group had stage III or IV disease at the time
f surgery. Additionally, 3-year survival was improved in
he multimodality group (32% vs 6%), and median survival
as significantly longer in the multimodality group (16 vs
1 months). Weaknesses of this study included the poor
ate of survival in the surgery monotherapy group, as well as
he inclusion of some gastric cardia cancers in the study
roup.
A second study performed at University of Michigan
howed less conclusive data.52 This randomized con-
rolled trial of 100 patients with both squamous cell
arcinoma and adenocarcinoma of the esophagus com-
ared surgery vs radiation combined with a chemother-
py regimen of 5-fluorouracil, cisplatin, and vinblastine.
nlike the study by Walsh et al,51 this study showed
nly an insignificant trend toward improved survival at 3
ears in the multimodality group (30% vs 16%; P 
15). The absolute difference between the groups, al-
hough not statistically significant, is certainly clinically
ignificant, but the study was not powered to detect
elatively small absolute differences in survival.
Given the conflicting nature of the data, as well as the
hortcomings of the studies considering this question,
any centers continue to practice multimodality neoad-
uvant therapy for subjects with adenocarcinoma of the
sophagus. Although some authorities have divergent





















































































May 2005 BARRETT’S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA 1557enefit from neoadjuvant therapy in the setting of esoph-
geal adenocarcinoma,55 given the low likelihood of com-
lete resection of disease in the absence of neoadjuvant
herapy, this practice will likely continue in the absence
f further definitive data.
Also becoming better understood is the optimal sur-
ical approach to resection of cancer. Radical en bloc
esection includes a laparotomy, a thoracotomy, and a
ervical approach. This approach allows for extensive
ymph node sampling and good assessment of extent of
isease. Alternatively, transhiatal approaches involve dis-
ection of the esophagus solely by use of abdominal and
ervical approaches, thus obviating thoracotomy. A re-
ent randomized controlled trial of the 2 approaches
howed that neither was statistically superior to the other
n 5-year survival, although the en bloc methods did
rovide an insignificant trend toward improved survival
39% for en bloc and 29% for transhiatal).56 These
esults show that surgical approach is not a major pre-
ictor of survival and that individual factors, such as
reoperative assessment of extent of disease and patient
omorbidities, may best decide which approach is most
ppropriate. For instance, transhiatal resection might be
ost appropriate for the elderly patient with limited
isease, whereas a more aggressive approach might be
dopted in the younger, healthier patient with more
xtensive disease.
Perhaps the clearest message from the surgical litera-
ure is that the experience of the surgeon and the volume
f the center providing the treatment are crucial predic-
ors of the morbidity of the treatment.57,58 Low-volume
urgeons have average 30-day mortality rates of 18.7%
or esophagectomy, whereas high-volume surgeons have
orresponding rates59 of 9.2% (Figure 1). These differ-
nces are likely due both to the greater experience of the
igure 1. Thirty-day mortality of surgical esophagectomy as a function
f the experience of the surgeon. Mortality approximately doubles
rom relatively inexperienced surgeons to high-volume practitioners.
Data adapted from Birkmeyer et al.59)urgical operators and to the specialized institutional aupport—such as skilled nursing, respiratory therapy,
nd intensive care units—that evolves in high volume
enters. Morbidity for this procedure is also impressive,
nd serious postsurgical complications have been re-
orted in more than 50% of subjects in some series.60,61
n addition to the perioperative risks noted previously,
he propensity of the esophageal remnant to develop
ecurrent BE above the anastomosis is becoming better
ecognized. Studies of subjects after esophagectomy show
hat 47% have some columnar epithelium in the tubular
sophagus and that approximately 10% develop BE.62,63
What Is the Best Treatment for High-Grade
Dysplasia?
Given the uniformly poor survival reported in
eries of patients with esophageal adenocarcinoma pre-
enting symptomatically, many centers in the United
tates have developed endoscopic surveillance programs
or patients with BE. Subjects are endoscopically assessed
t fixed intervals, and intervention is contemplated on
he basis of the degree of dysplasia noted on surveillance
iopsies. Subjects with nondysplastic BE are generally
ollowed up at intervals of 2–3 years, whereas those with
GD are considered for intervention.64 Of current de-
ate is the most appropriate care for those with HGD.
The presence of HGD is considered an appropriate
riterion for surgical resection in many medical centers.
roponents of this position cite the high risk of progres-
ion, as well as the likelihood of metachronous cancer, as
oted previously.37,65–69 Recently, 2 other potential
anagement strategies have been put forward. Intensive
ndoscopic surveillance relies on the principle that su-
erficial adenocarcinoma of the esophagus rarely has
ymph node involvement. Therefore, if early detection
fforts are rigorous enough, survival should not be neg-
tively affected even if a substantial proportion of the
ohort does progress to cancer. These subjects would go
n to get the surgery that they would have gotten
nyway and to be cured of disease, whereas the remainder
f the cohort is spared a morbid surgery and the subse-
uent attendant decrease in quality of life from living
fter esophagectomy. To date, only 1 large cohort has
een reported with this approach. Seventy-five subjects
ith HGD were followed up by Schnell et al38 with
ntensive endoscopic surveillance in a cohort study at the
ines Veterans Administration in Chicago. These sub-
ects underwent intensive endoscopic surveillance (every
months for the first year, every 6 months for the second
ear, and yearly thereafter). At a mean follow-up of 7.3
ears, only 16% of the cohort had developed cancer. The
emainder of the group was cancer free with the esoph-


































































































1558 NICHOLAS J. SHAHEEN GASTROENTEROLOGY Vol. 128, No. 6ver that time, but only a single person had died from
etastatic esophageal cancer. This individual was a pa-
ient who had been lost to follow-up for 10 years after his
iagnosis of HGD and who presented after that period
ith widely metastatic disease.
It is unclear why the prognosis of HGD in the
ines Veterans Administration cohort was superior to
hat in other previously reported groups with HGD.34
ecause this cohort underwent an extensive search for
etachronous cancer before patients were enrolled in
he surveillance program, some of the difference may
e more apparent than actual—the group was better
purified” of metachronous cancer than other reported
ohorts. Other alternative explanations include the
ossibility that variability between centers in the his-
ological definition of HGD might explain these re-
ults. Certainly, if the Hines Veterans Administration
atients with HGD had a less severe form of dysplasia
han HGD patients in other cohorts, this finding
ight explain the discrepancy in the data. Regardless
f these issues, on the basis of these data, some centers
ave been offering intensive endoscopic surveillance as
n alternative to resection. This approach might be an
specially attractive option in subjects who are poor
urgical candidates or who are elderly. In such sub-
ects, who might be most prone to a complication
rom interventions such as surgery or ablative therapy,
ntervention (and the risks associated with it) could be
argeted to only that subgroup who went on to de-
elop superficial cancer. Also, unifocal HGD (ie, HGD
ound on only 1 of a number of biopsy samples taken
or endoscopic surveillance) might have a better prog-
osis than multifocal HGD.70 If so, perhaps unifocal-
ty of disease might be a reasonable criterion for
onsidering intensive endoscopic surveillance.
One rapidly evolving area of investigation in the treat-
ent of HGD is the use of endoscopic ablative therapies.
hese modalities offer the promise of diminishing the
ancer risk in the setting of HGD while avoiding the
orbidity and mortality of esophagectomy.
Multiple different modalities have been described,
ncluding electrocoagulation therapy, lasers,71–73 argon
eam coagulation therapy,74–76 yttrium–aluminum–gar-
et laser therapy,77,78 radiofrequency ablation,79 and pho-
odynamic therapy (PDT).80,81 Of all the modalities
vailable, perhaps the most extensive available experience
n the literature is with PDT. PDT relies on the inter-
ction of a chemical compound, porfimer sodium, with
ight of a specific wavelength (630 nm) to cause an
ntracellular reaction that results in the death of the cell.
reatment of the affected segment of BE for a preset
eriod of time results in a predictable degree of tissue mamage, such that tissue destruction is deep enough to
estroy most or all of the BE cells but not deep enough
o cause full-thickness necrosis of the esophagus with
ubsequent perforation (Figure 2).
A controlled trial of subjects randomized to either
DT therapy with high-dose proton pump inhibition or
roton pump inhibition alone has recently been per-
ormed.82 All subjects in the study had BE with HGD.
his study, the result of which is currently available only
n abstract form, shows a greater than 50% reduction in
he number of subjects who developed adenocarcinoma
n the group treated with PDT (28% vs 13%; P  .006).
iven these data, as well as uncontrolled data suggesting
hat ablation of HGD provides diminution of the cancer
isk compared with historical controls,81 PDT has been
pproved by the US Food and Drug Administration as a
reatment of BE with HGD.
Two conflicting concerns regarding the performance
f PDT are the subsequent stricture rate in subjects
ndergoing the procedure and the likelihood of sub-
ucosal Barrett’s glands under the neosquamous epi-
helium. These concerns are in a way complemen-
ary—ablative modalities that provide the deepest
ucosal burn, such as PDT, feature relatively low
ates of buried glands but higher rates of stricture.
he opposite seems true of more superficial treatments
f BE, such as argon beam coagulation, which are
ssociated with a lesser rate of stricturing but more
uried glands.83 The stricture rate associated with 1
reatment of PDT approximates 20% and increases to
pproximately 50% if multiple treatments are neces-
ary.81,84 These strictures are amenable to endoscopic
herapy, but, because the strictures are thick and
brous, multiple sessions of dilation may be necessary
efore good relief of dysphagia is obtained. Concom-
tant therapy with steroids does not decrease the sub-
equent stricture rate in subjects undergoing PDT.80
he rate of retained buried Barrett’s glands under
ormal-appearing squamous mucosa is less well de-
cribed. Clearly, these glands have the potential to
rogress through stages of dysplasia to cancer, because
everal case reports of submucosal adenocarcinoma in
ubjects with apparently normal neosquamous epithe-
ium have been described.85– 87 Whether the neosqua-
ous epithelium itself has an increased risk of squa-
ous cancer is similarly unclear.
Given the current state of the data, a reasonable ap-
roach to the patient with HGD might be consideration
f either ablative therapy or intensive surveillance for
hose with unifocal disease. For those with multifocal
















































May 2005 BARRETT’S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA 1559Endoscopic Mucosal Resection: An Evolving
Place in the Treatment Armamentarium
Because of the morbidity and mortality associated
ith esophagectomy, as noted previously, investigators
ave become increasingly bold in their efforts at endolu-
inal therapy for superficial esophageal cancers and pol-
poid HGD. Endoscopic mucosal resection (EMR) offers
he promise of definitive treatment of these lesions with
less invasive approach than thoracotomy. Several dif-
erent endoscopic techniques have been developed. Piece-
eal resection using a saline lift technique imitates the
echnique used for sessile colonic adenomas.88 This lift
echnique can be used in association with snare removal
f the lesion. Other lesions may be amenable to resection
ith a banding technique similar to that used for esoph-
geal varices; a snare is used to remove the pseudopolyp
roduced after banding so that the specimen can be sent
o pathology to ensure complete removal.88–90 Finally,
ovel EMR resection caps, with a beveled edge and a
nare that fits along a groove at the top of the cap, have
een described.91 These caps may be positioned over the
esion of interest, after which suction is applied, and the
esion is pulled into the cap. The snare is tightened over
he base of the lesion, which is then truncated. This
ethod is especially useful for larger lesions, which will
ot easily fit in a variceal ligation cap.
Reports regarding the success of EMR at removing
uperficial lesions have been largely positive; however,
he evidence to date consists of mostly case series, and
ublication bias may inflate the value of these proce-
ures. Multiple endoscopic procedures may be necessary
o accomplish complete removal of the lesion. With
espect to the recurrence of cancer, most series report
ittle or no progression to more advanced cancer. How-
ver, it should be noted that most reported series noted
reviously feature a mean follow-up of less than 24
onths.
Recently, attempts have been made to treat large
ortions of mucosa with HGD but no masses or nodules
y using EMR to remove portions of columnar epithe-
ium, as opposed to discrete lesions.92 Although prelim-
nary experience with these techniques has been encour-
ging, the relatively large portions of the mucosa that
equire resection, as well as the preliminary nature of
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
igure 2. Typical findings in photodynamic therapy for Barrett’s
sophagus. (A) A typical segment of BE with HGD. (B) Extensive
ucosal necrosis is evident 48 hours after application of the laser to
he mucosa, which was pretreated with photofrin. (C) The area of












































































1560 NICHOLAS J. SHAHEEN GASTROENTEROLOGY Vol. 128, No. 6hese reports, make total removal of BE by endoscopic
esection a procedure best performed as part of a clinical
rial. Currently, large-scale EMR of nonnodular BE is not
ecommended as a standard practice.
Chemoprevention of Esophageal
Adenocarcinoma
Extensive observational data substantiate that
onsteroidal anti-inflammatory drugs (NSAIDs) are as-
ociated with a 50% or greater decrease in esophageal
ancer.93–96 The exact mechanism of any chemopreven-
ive effect is unclear, and no randomized controlled trial
as confirmed that this observed association is causative.
owever, given the poor prognosis associated with
sophageal cancer, authorities have suggested the poten-
ial use of chemoprevention in the setting of BE.97
specially in subjects with HGD, such chemoprevention,
f effective, might markedly reduce the risk of cancer.
ndeed, cost-effectiveness analyses have suggested that
hemoprevention for HGD might be a very cost-effective
aneuver. A recent cost-effectiveness model98 examining
he utility of aspirin as a chemopreventive agent in
ssociation with surveillance endoscopy showed that,
ompared with no therapy, an additional quality-ad-
usted life-year could be obtained for an acceptable cost
f $49,600. A second analysis also suggested that che-
oprevention with NSAIDs provided gains in life ex-
ectancy at potentially reasonable costs.99 These calcula-
ions assume, of course, that NSAID use retards the
rogression of HGD to cancer. If the actual mechanism
f chemoprevention of cancer by NSAIDs is to prevent
he initial formation of BE, it may well be that attempts
t treating HGD with NSAIDs to stop cancer are fruit-
ess, because the critical point for intervention has al-
eady been missed. Recent work has concentrated on the
otential use of cyclooxygenase 2 inhibitors as chemo-
reventive agents. It was hoped that a superior side-effect
rofile of these agents compared with nonselective
SAIDs might improve the risk–benefit ratio of chemo-
revention. However, given recent revelations about po-
ential cardiac side effects with rofecoxib,100 the use of
yclooxygenase 2 inhibitors as chemoprevention in the
etting of BE is not currently advisable.
Another recent topic of interest has been the effect of
igorous acid inhibition with proton pump inhibitors on
he natural history of BE. Early after the advent of proton
ump inhibitors, multiple studies showed that proton
ump inhibitor therapy did not lead to the reliable
egression of BE.101–103 Recently, however, longitudinal
ohort studies of subjects with BE have suggested that
he use of proton pump inhibitors may be associated with Jdecreased risk of dysplasia in the BE104,105 (Figure 3).
n vitro work suggests that pulsed acid exposure pro-
otes proliferation of cell cultures of BE.106 It may be
hat the chronic inflammation associated with ongoing
ERD promotes carcinogenesis. If so, then acid suppres-
ion of subjects with BE may retard the progression to
ancer. It is unclear presently whether subjects with BE
eed to undergo acid suppression to the point of com-
lete obliteration of esophageal acid exposure or whether
ess rigorous acid suppression will still confer any bene-
ts against progression of disease. Although the effect of
igorous acid suppression on the likelihood of progres-
ion of BE is unclear, the common occurrence of reflux
ymptoms in these patients and the benign nature of the
ntervention make it reasonable to maintain these pa-
ients on acid suppression with a proton pump inhibitor.
Does Endoscopic Screening of
Subjects With Chronic
Gastroesophageal Reflux Disease
Symptoms Prevent Death From
Esophageal Adenocarcinoma?
Endoscopic screening of subjects with chronic
ERD symptoms has been proposed as a method for
etecting subclinical cancers, as well as BE. Subjects
ound to harbor BE could then be entered into surveil-
ance programs designed to monitor the lesion for pro-
ression.64 Although data in support of the efficacy of
his approach are lacking, the practice is widespread
mong gastroenterologists.107
Recommending organizations are somewhat conflicted
s to the appropriate approach for screening subjects with
igure 3. Dysplasia risk as a function of acid-suppressive therapy. In
36 US veterans with nondysplastic BE, El-Serag et al.105 showed
hat protection from dysplasia development was strongly associated
ith proton pump inhibitor (PPI) therapy (Reprinted from the American




































































































May 2005 BARRETT’S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA 1561hronic GERD. The Practice Parameters Committee of
he American College of Gastroenterology notes in their
ost recent guidelines that “patients with chronic
ERD symptoms are those most likely to have Barrett’s
sophagus and should undergo upper endoscopy.”64 This
nce-in-a-lifetime endoscopy would screen for BE and
llow enrollment of eligible subjects into surveillance
rotocols. Conversely, at a recent American College of
astroenterology Consensus Conference, a multidisci-
linary panel of 18 experts in BE believed that there was
nsufficient evidence to accept the proposition that
creening for BE improved mortality from adenocarci-
oma or was cost-effective.108 Contrary to the American
ollege of Gastroenterology clinical guidelines, the
merican College of Gastroenterology participants did
ot believe that adequate data were available to support
creening for adults over older than 50 years, regardless
f age or duration of heartburn.
The source of this discrepancy of opinion lies in the
ack of convincing data to show any beneficial effect of
creening endoscopy, as well as the substantial theoreti-
al concerns about the effectiveness and cost-effectiveness
bout such an approach. The data supporting screening
pper endoscopy are weak. Patients who have their can-
ers detected as part of an endoscopic screening and
urveillance program have their lesions discovered at an
arlier stage and are more often eligible for surgical
esection. Also, the life expectancy of individuals with
sophageal adenocarcinoma diagnosed by endoscopic
creening programs is longer than the life expectancy of
hose who present symptomatically.109–114 Although
ata such as these seem suggestive, several biases, includ-
ng lead-time and length bias,115,116 often accentuate the
pparent benefits of endoscopic screening and surveil-
ance programs in observational studies. Therefore, the
nly available data supporting screening endoscopy are
bservational and subject to bias.
However, substantial theoretical concerns argue
gainst the effectiveness of screening upper endoscopy
or those with GERD. First, the ubiquity of GERD in
he United States means that the pool of subjects to be
creened is enormous. Even if we limit potential
creenees to those older than the age of 55 years with
t least weekly GERD symptoms, according to US
ensus statistics and our knowledge of the epidemiol-
gy of GERD, more than 10 million subjects in the
nited States would be eligible for screening (Figure
). Second, the cancer that we are trying to prevent is
elatively rare; a little more than half of the 14,250
ases of esophageal cancer in the United States in 2004
re expected to be adenocarcinomas.117 Third, a large
ortion of those with adenocarcinoma never experience lignificant reflux symptoms. Case-control studies sug-
est that approximately 40% of those with adenocar-
inoma never experienced reflux symptoms before
heir cancer diagnosis.15,16 Clearly this group would
ot benefit from screening programs aimed at those
ubjects with reflux symptoms. Next, the age of onset
or this cancer in most series is in excess of 70 years.
any patients of that age have significant comorbidi-
ies that make effective intervention difficult and limit
he number of life-years that can be saved even if
ffective intervention is attained.15,118 In fact, longi-
udinal studies show that those with BE have the same
urvival as age- and sex-matched controls without BE
rom the general public.119,120 Finally, even if upper
ndoscopy is obtained before the diagnosis of cancer,
E might not be correctly identified, and the subject
ight not be entered in a surveillance program. In a
ecent retrospective cohort study in the Kaiser Perma-
ente group in California, out of 64 patients who
eveloped adenocarcinoma and had an upper endos-
opy before the development of cancer, only 23 had
dentification of BE.121 Whether short segments of BE
ere missed on endoscopy in the remaining 64% of
atients or whether their cancer did not originate in
egments of BE is unknown.
These barriers to effective screening are com-
ounded by the fact that our screening test, upper
ndoscopy, is relatively expensive. Also, although it is
very safe test, because the yield with respect to
ancer is so low, the number of cancers averted may be
ivaled by the number of complications of endos-
opy.122–125 Although some cost analyses have sug-
ested that screening and surveillance may be cost-
ffective,126,127 the authors note that the results of
hese analyses are sensitive to several poorly defined
ariables. It is interesting to note that 1 recent anal-
sis suggested that although an initial endoscopic
creening looking for BE with dysplasia was cost-
ffective, subsequent endoscopic surveillance of sub-
ects with nondysplastic BE was highly cost-prohibi-
ive.128
At this juncture, it is highly unlikely in the United
tates that a randomized trial of endoscopic screening
nd surveillance vs usual symptomatic care of GERD
ill ever be performed. However, data may become
vailable from other countries where endoscopic
creening and surveillance are not widely practiced. In
he meantime, clinicians will need to weigh the risks
nd possible benefits of screening on a case-by-case
asis, and all decisions on the subject should be pref-
ced with a frank discussion with the patient about the
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roups,129 may improve the effectiveness of these prac-
ices.
Conclusion
Despite some strides in our understanding of
he pathophysiology and treatment of the disease,
sophageal adenocarcinoma remains a deadly tumor.
lthough it is rare in the United States, the incidence
f this disease has increased rapidly in the last 40
ears, commanding the attention of clinicians and
akers of public health policy. Many centers special-
zing in the care of this cancer perform neoadjuvant
hemoradiation, although the benefits of this approach
re unclear. In an effort to avoid the morbidity asso-
iated with esophagectomy, rapid evolution has oc-
urred in the endoscopic treatments of superficial ad-
nocarcinoma and BE with HGD. Although the
esults of these techniques are promising, most fol-
ow-up to date is short-term, and the effectiveness of
hese therapies is not fully elucidated.
Although chemoprevention in the setting of BE
igure 4. Performance of a hypothetical national screening program
or esophageal adenocarcinoma. Given the vast number of subjects
ith chronic GERD symptoms who would need to be screened, even if
e limited our screening to those older than the age of 50 years, more
han 10 million Americans might be eligible for screening. We know
hat the absolute number of cancers approximates 8000 per year and
hat almost half of these occur in subjects without significant chronic
ERD. Although upper endoscopy is a safe procedure, such a program
ight have more major endoscopy complications than cancers dis-
overed (data adapted from Shaheen and Ransohoff130). CA, cancer;
o, years old.ith NSAIDs, proton pump inhibitors, or both maye of benefit, randomized data are lacking to prove
his. Because most subjects with BE undergo initial
nvestigation because of GERD symptoms, proton
ump inhibitor therapy, both for symptomatic relief
nd any benefit conferred from slowing progression to
ysplasia, seems warranted in subjects with BE. Al-
hough widely practiced, endoscopic screening of
hose with chronic GERD symptoms, with enrollment
f subjects with BE into endoscopic surveillance pro-
rams, is of unclear benefit.
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